There’s “no reason” for the U.S. Drug Enforcement Administration to delay its long-awaited decision on moving marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act, the head of the Food and Drug Administration told a House committee.
However, FDA Commissioner Robert Califf seemed to hint Thursday that the DEA could treat adult-use marijuana – now legal in 25 states – differently than cannabis used for medicinal purposes.
ADVERTISEMENT
Such a “bifurcation,” if applied to rescheduling, could have a profound impact on the U.S. marijuana industry, analysts observed Friday.
Tax relief for MMJ, not adult use?
It could mean medical marijuana businesses would enjoy tax relief that adult-use operators wouldn’t.
Califf’s comments came as part of a much lengthier and broader hearing
Read full article on Marijuana Business Daily
